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Summary
Gene-targeted mice have recently revealed a role for
lymphocytes and interferon- (IFN) in conferring
protection against cancer, but the mechanisms re-
main unclear. Here, we have characterized a success-
ful primary antitumor immune response initiated by
naive CD4+ T cells. Major histocompatibility complex
class II (MHC-II)-negative myeloma cells injected sub-
cutaneously into syngeneic mice were surrounded
within 3 days by macrophages that captured tumor
antigens. Within 6 days, naive myeloma-specific CD4+
T cells became activated in draining lymph nodes and
subsequently migrated to the incipient tumor site.
Upon recognition of tumor-derived antigenic peptides
presented on MHC-II by macrophages, the myeloma-
specific CD4+ T cells were reactivated and started to
secrete cytokines. T cell-derived IFN activated mac-
rophages in close proximity to the tumor cells. Tumor
cell growth was completely inhibited by such locally
activated macrophages. These data indicate a mecha-
nism for immunosurveillance of MHC-II-negative can-
cer cells by tumor-specific CD4+ T cells through col-
laboration with macrophages.
Introduction
The immune system has been proposed to specifically
recognize and eliminate newly transformed cells (Bur-
net, 1970). A series of reports with gene-targeted mice
have recently provided strong experimental support for
this cancer immunosurveillance hypothesis. Mice defi-
cient for IFNγ, IFNγ receptor, perforin, NKT cells, αβ T
cells, γδ T cells, or both T and B cells (Rag2−/−) are all
more susceptible to spontaneous or carcinogen-induced
cancer (Girardi et al., 2001; Kaplan et al., 1998; Shan-
karan et al., 2001; Smyth et al., 2000a, 2000b; Street
et al., 2002). These studies in animals support earlier
observations that humans with a reduced immune ca-
pacity are more prone to develop malignancies (Birke-
land et al., 1995; Gatti and Good, 1971). However, the*Correspondence: alexandre.corthay@medisin.uio.no (A.C.); bjarne.
bogen@medisin.uio.no (B.B.)
3 These authors contributed equally to this work.mechanisms of cancer immunosurveillance remain to
be elucidated.
Our present knowledge of how T cells eliminate can-
cer is almost exclusively based on memory immune re-
sponses investigated with vaccinated mice (Gross,
1943; Lynch et al., 1972). Such studies have revealed
the critical role of tumor-specific CD4+ T cells in helping
cytotoxic CD8+ T cells to kill tumor cells (Ossendorp et
al., 1998). In addition, CD4+ T cells themselves can re-
ject tumors in the absence of CD8+ T cells (Fujiwara et
al., 1984; Levitsky et al., 1994; Mumberg et al., 1999). It
has been proposed that CD4+ T cells eliminate tumors
through activation and recruitment of effector cells, in-
cluding macrophages and eosinophils (Hung et al.,
1998). Several studies suggest that cytokines such as
IFNγ that are secreted by type I (Th1) CD4+ T cells might
be involved in antitumor and antiangiogenic activities
(Mumberg et al., 1999; Qin and Blankenstein, 2000). Un-
fortunately, despite these findings in vaccinated mice,
it is presently unclear whether similar mechanisms ap-
ply in immunosurveillance, i.e., during the course of a
primary antitumor immune response.
The tumor protective role of CD4+ T cells has been
conceptually problematic since most tumor cells do not
express MHC-II and thus cannot be directly recognized
by tumor-specific CD4+ T cells. Therefore, rejection of
MHC-II-negative tumor cells by CD4+ T cells is most
likely dependent on professional antigen-presenting
cells (APCs) that endocytose, process, and present tu-
mor antigens on their MHC-II to tumor-specific CD4+ T
cells. This hypothesis is supported by the observation
that dendritic cells isolated from large tumors are
loaded with tumor antigens and can activate tumor-
specific CD4+ T cells (Dembic et al., 2000, 2001). How-
ever, it is presently not known whether APCs can effi-
ciently activate tumor-specific CD4+ T cells during a
primary immune response, when the tumor load is still
very low.
In order to study the mechanisms of cancer immuno-
surveillance by CD4+ T cells, we used a T cell receptor
(TCR)-transgenic mouse system (Lauritzsen et al.,
1994). In these transgenic mice, T cells recognize a tu-
mor-specific idiotopic (Id) peptide from the secreted
immunoglobulin (Ig) L chain V region of the MOPC315
mouse myeloma, presented in the context of MHC-II
I-Ed (Bogen et al., 1986). The TCR-transgenic mice were
made homozygous for the severe combined immuno-
deficiency (SCID) mutation, which ensures the unique
specificity of the T cells by preventing rearrangement
of endogenous TCR chains (Bogen et al., 1995). The
high frequency of naive tumor-specific CD4+ T cells in
TCR-transgenic mice renders the mice resistant against
subcutaneous (s.c.) injection with syngeneic MOPC315
tumor cells, whereas nontransgenic mice develop fatal
tumors. Protection is Id specific, CD4+ T cell mediated,
and does not require the presence of B cells, γδ T cells,
and CD8+ T cells (Bogen et al., 1995; Lauritzsen et al.,
1994). Importantly, MOPC315 lacks MHC-II and there-
fore cannot be directly recognized by transgenic Id-
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aand Bogen, 1993). However, in large tumors, infiltrating
APCs are Id primed and stimulate Id-specific CD4+ T r
scells (Dembic et al., 2000, 2001). Rejection of MOPC315
by the Id-specific TCR-transgenic mice does not re- g
rquire immunization of the mice, and thus represents a
genuine primary immune response.
It has been difficult to study the mechanisms of tu- T
mor rejection in Id-specific TCR-transgenic mice, be- i
cause the myeloma cells could not be precisely local- T
ized in vivo after injection. To solve this, we have in this P
study embedded injected tumor cells in a collagen gel s
(Matrigel), which enabled us to analyze the early in- a
teractions between tumor cells and infiltrating cells t
from the host, during a primary antitumor immune re- a
sponse. a
o
iResults
n
sTCR-Transgenic SCID Mice Are Protected
dagainst MOPC315 Myeloma Cells Injected
Min Phosphate-Buffered Saline or Matrigel
aIn accordance with a previous report (Bogen et al.,
a1995), Id-specific TCR-transgenic SCID mice were re-
ssistant against s.c. challenge with MOPC315 cells in-
tjected in phosphate-buffered saline (PBS), whereas
wnontransgenic SCID littermates developed fatal tumors
m(Figure 1A). To estimate the kinetics of rejection, serum
1concentrations of myeloma protein M315 were mea-
sured at several time points after injection by enzyme-
slinked immunosorbent assay (ELISA) (Figure 1B). In
nmost control SCID mice, M315 levels increased expo-
(nentially, reflecting progressive s.c. tumor growth (Fig-
mure 1B, left). By contrast, in all TCR-transgenic SCID
(mice, M315 levels were low (<350 ng/ml) throughout the
2experiment (Figure 1B, right). In 9 out of these 18 TCR-
Ttransgenic SCID mice, M315 remained undetectable in
tserum (detection level: 1 ng/ml). In the other 9 mice,
othe serum concentration of M315 increased slowly until
sdays 8–11, suggesting that the tumor cells underwent
Ca limited in vivo expansion during the first days after
2injection. After day 11, however, serum M315 levels de-
ccreased in all TCR-transgenic SCID mice, reflecting the
pelimination of the tumor cells. These data strongly sug-
Bgest that the effector functions of the antitumor im-
imune response are activated well before day 11 after
Tinjection, and that the tumor cells are completely re-
ajected by day 15.
tIn order to precisely localize the injected tumor cells
sin the host, we embedded MOPC315 cells in a collagen
igel (Matrigel) that is soluble at +4°C but gels at body
Ttemperature, resulting in a plug that can easily be iden-
ftified in vivo (Kleinman et al., 1986). Another advantage
iof this technique is that it traps the infiltrating host cells
i(see below). TCR-transgenic SCID mice were effectively
oprotected against MOPC315 injected in Matrigel for
more than 50 days after injection (Figure 1C). However,
most transgenic mice failed to completely reject the M
tmyeloma cells injected in Matrigel, as revealed by low
but sustained levels of serum M315 (Figure 1D). As a T
aconsequence of this incomplete rejection, slow-grow-
ing tumors developed in three out of seven TCR-trans- i
igenic SCID mice as late as 60–90 days after the injec-ion (Figure 1C). As with MOPC315 injected in PBS, the
ntitumor immune response against MOPC315 in Mat-
igel was rapid, since as early as 12 days after injection,
erum M315 levels were significantly lower in trans-
enic mice compared to SCID controls (Figure 1D,
ight).
umor-Specific CD4+ T Cells Become Activated
n Draining Lymph Nodes, Migrate to the Incipient
umor Site, and Secrete Cytokines
roliferation of tumor-specific CD4+ T cells was first ob-
erved in the lymph node (LN) draining the injection site
t day 3 and dramatically increased at day 6 after injec-
ion of MOPC315 in either Matrigel or PBS (Figure 2A
nd data not shown). This clonal expansion was associ-
ted with upregulation of the activation marker CD69
n most tumor-specific CD4+ T cells (Figure 2A). The
mmune response was local, as similar changes were
ot observed in nondraining LN or spleen (data not
hown; also, see below). The T cell activation was not
ue to Matrigel per se because injection of cell-free
atrigel gave no response on day 6. Moreover, T cell
ctivation was Id specific since no response was seen
fter injection with the control J558 myeloma, which
ecretes a monoclonal IgA with V regions different from
hose of MOPC315 (Figure 2A). This is in accordance
ith previous reports showing that the TCR-transgenic
ice reject MOPC315, but not J558 cells (Bogen et al.,
995; Lauritzsen et al., 1994).
From days 3–9 after tumor cell injection, the tumor-
pecific CD4+ T cells differentiated in draining LN from
aive to memory phenotype: the cells increased in size
blast formation), upregulated surface CD11a and CD44
olecules, downregulated CD62L, and synthesized DNA
i.e., incorporated bromodeoxyuridine, BrdU) (Figure
C, left and data not shown). Since CD44hiCD62Llo
cells have the capacity to enter nonlymphoid tissues,
hese data prompted us to analyze the cellular content
f MOPC315-containing Matrigel plugs. At day +6, a
mall but distinct population of Matrigel-infiltrating
D69+ tumor-specific T cells could be detected (Figure
B). At day +9, Matrigel-infiltrating tumor-specific T
ells were more frequent and had a typical memory
henotype (enlarged size, CD11ahi, CD44hi, CD62Llo/−,
rdU+) (Figure 2C, right). Importantly, these Matrigel-
nfiltrating tumor-specific T cells were producing the
h1 cytokines IFNγ and tumor necrosis factor α (TNFα)
t day +11 (Figure 2D). In the same experiment, in-
erleukin-2, but not granulocyte/macrophage colony-
timulating factor (GM-CSF), was detected in Matrigel-
nfiltrating tumor-specific CD4+ T cells (data not shown).
hese results demonstrate that 11 days are sufficient
or the priming of tumor-specific CD4+ T cells in drain-
ng LN, the migration of primed T cells into the tissue
n which the tumor cells are located, and the secretion
f cytokines.
assive Recruitment of Host Cells
oward the Injected Myeloma Cells
he early in vivo interactions between the tumor cells
nd cells of the immune system were visualized by
mmunostaining of MOPC315-containing Matrigel plugs
n TCR-transgenic SCID mice (Figure 3). Figure 3A
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373Figure 1. TCR-Transgenic SCID Mice Are Protected against MOPC315 Myeloma Cells Injected in PBS or Matrigel
(A–D) TCR-transgenic SCID and SCID littermates were injected s.c. with MOPC315 cells in (A and B) PBS or in (C and D) Matrigel. (A and C)
Tumor development was followed by palpation, and (B and D) serum myeloma protein M315 concentration was measured by ELISA. Mice
with large tumors (diameter >10 mm) were euthanized. P values were calculated with the (A and C) logrank test and the (D) Mann-Whitney test.shows a s.c. day +6 Matrigel plug containing islets of
tumor cells (arrows). Recruitment of blood leukocytes
toward the MOPC315-containing Matrigel plug was
suggested by the appearance of nucleated cells within
blood vessels at the periphery of the plug (day +3, Fig-
ures 3B and 3C). At day +6, the nucleated (Hoechst+)
cells inside the Matrigel plug can basically be divided
into two distinct populations: (i) the MOPC315 cells
growing in islets and stained by the myeloma marker
CD138 (syndecan-1), and (ii) the host cells that essen-
tially all expressed MHC-II (Figure 3D). These MHC-II+
host cells formed a dense layer covering the edge of
the myeloma-containing Matrigel plug 3–6 days after
injection (arrows in Figures 3D and 3F). Numerous
MHC-II+ host cells were seen penetrating the Matrigel
plug, of which several were in close contact with the
CD138+ myeloma cells (arrows in Figure 3E). The Matri-
gel-infiltrating MHC-II+ cells coexpressed the macro-
phage marker F4/80 (day +3, Figure 3F). Figure 3G
shows a MHC-II+ cell crossing the endothelium of a
blood vessel inside a Matrigel plug. Collectively, these
data suggest that there is a massive recruitment of host
MHC-II+ macrophages toward the tumor cells. These
macrophages are most likely derived from blood mono-
cytes that extravasated mainly from vessels situated atthe periphery of the plug, but also from vessels sur-
rounded by the gel. Additionally, infiltrating T cells
could be detected in Matrigel sections, but they were
much fewer than the macrophages. Importantly, some
tumor-specific T cells apparently made contact with
MHC-II+ macrophages in the MOPC315-containing Ma-
trigel plug (Figure 3H).
Matrigel-Infiltrating MHC-II+ Cells
Are Mostly Macrophages
We next used flow cytometry to characterize the Matri-
gel-infiltrating MHC-II+ cells 1–6 days after injection.
For these experiments, green fluorescent protein (GFP)-
transduced MOPC315 cells were used, allowing a sim-
ple and effective detection of tumor cells. Analysis of
the cellular content of a Matrigel plug at day +5 revealed
a massive infiltration of cells expressing the CD11b
(Mac-1) myeloid cell marker (Figure 4A). MHC-II expres-
sion was almost exclusively restricted to these CD11b+
cells (R1 in Figure 4A), whereas GFP+ MOPC315 cells
were MHC-II negative (R3). A large population of
CD11b−GFP− cells that were essentially devoid of
MHC-II expression was also detected in Matrigel (Fig-
ure 4A, R2). Most of these triple-negative cells were most
likely MOPC315 cells that had lost GFP expression (un-
Immunity
374Figure 2. Naive Tumor-Specific CD4+ T Cells Become Activated in Draining LN, Migrate to the Incipient Tumor Site, and Produce Cytokines
TCR-transgenic SCID mice were injected s.c. with Matrigel containing either tumor cells (MOPC315 or control J558) or PBS only and were
analyzed by flow cytometry.
(A) Numbers of tumor-specific (detected by the clonotype-specific GB113 mAb) CD4+ T cells in draining LN 1–6 days after injection. Each
column represents the mean of three mice (pooled organs). Hatched areas represent the proportion of activated (CD69+) cells.
(B) At day +6, a MOPC315-containing Matrigel plug was digested with collagenase/DNase to release the cells, and infiltrating tumor-specific
T cells were detected by double staining with anti-TCRCβ and GB113 mAb. Insert, CD69 expression on gated TCRCβ+GB113+ T cells.
(C) Phenotype of tumor-specific CD4+ T cells in draining LN and within the MOPC315-containing Matrigel plug at day +9 (boldface line). For
comparison, LN cells from naive, uninjected TCR-transgenic SCID mice were stained and gated similarly (shaded area). The specificity of the
BrdU staining was controlled by using mice not treated with BrdU (thin line).
(D) Matrigel-infiltrating tumor-specific CD4+ T cells were stained for intracellular IFNγ and TNFα at day +11, after a 6 hr in vitro stimulation
with ionomycin/PMA in the presence of monensin. The dotted line in (B) and (C) indicates an isotype-matched control mAb.published data), compatible with the immunostaining (
tdata which show that essentially all MHC-II-negative
cells in Matrigel stain positively for the myeloma marker b
lCD138 (Figure 3D). Further characterization of the Mat-
rigel-infiltrating CD11b+ cells identified the cells as typi- i
Tcal macrophages: they expressed CD11a (LFA-1 α chain),
CD54 (ICAM-1), CD80, CD86 and Mac-3 (Figure 4B), g
mwhile they were negative for CD45R/B220, CD4 and
CD8 (not shown). Interestingly, a minority (4%–12%) w
tof the Matrigel-infiltrating CD11b+ cells expressed
CD11c+, indicating a small subset of dendritic cells i
a(Figure 4B).
i
dTumor-Specific CD4+ T Cells Activate Matrigel-
pInfiltrating Macrophages
aThe immunostaining data revealed that some tumor-
uspecific CD4+ T cells made close contact with macro-phages inside MOPC315-containing Matrigel plugsFigure 3H). A functional consequence of such an in-
eraction could be the activation of the macrophages
y the CD4+ T cells. Indeed, after MOPC315 injections,
evels of the activation marker MHC-II on Matrigel-
nfiltrating macrophages were dramatically increased in
CR-transgenic SCID mice as compared to nontrans-
enic SCID mice (Figure 4C). Moreover, two additional
acrophage activation markers (CD11a and CD54)
ere upregulated on infiltrating macrophages in TCR-
ransgenic SCID mice (Figure 4B). This prompted us to
nvestigate the kinetics of macrophage recruitment and
ctivation. Large numbers of macrophages were found
n Matrigel plugs containing MOPC315 as early as 3
ays after injection, but, at this time point, MHC-II ex-
ression was not upregulated (Figure 4D). In contrast,
t day +6, most Matrigel-infiltrating CD11b+ cells had
pregulated MHC-II in TCR-transgenic mice (Figure4D), correlating with the influx of tumor-specific CD4+
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Myeloma-Containing Matrigel Plugs
(A–H) TCR-transgenic SCID mice were in-
jected s.c. in the flank with MOPC315 cells
in Matrigel. Tissue samples were taken for
(A–C) H+E staining or (D–H) immunohisto-
chemistry 3–10 days after injection. (A) Sub-
cutaneous day +6 Matrigel plug containing
MOPC315 cells. Examples of tumor islets are
shown by arrows. (B) Blood vessels in the
vicinity of a day +3 Matrigel plug (arrows, is-
lets of myeloma cells). (C) Higher magnifica-
tion of the insert in (B) showing the high
number of nucleated cells within the vessel
(arrows). (D and E) MHC-II+ (red) host cells
infiltrate a day +6 Matrigel plug containing
CD138+ (green) MOPC315 cells. Arrows in
(D) show the border of the plug. Arrows in (E)
show contacts between MHC-II+ cells and
CD138+ tumor cells. (F) The Matrigel-infil-
trating MHC-II+ (red) cells express the mac-
rophage marker F4/80 (green) at day +3.
Arrows show the border of the plug. (G)
MHC-II+ (red) cells penetrate deep into a day
+6 Matrigel plug. The edge of the plug is at
the top of the image. The insert shows a
MHC-II+ cell crossing the endothelium of a
von Willebrand factor+ (vWf+, green) blood
vessel in the interior of a Matrigel plug. (H)
In a day +10 MOPC315-containing Matrigel
plug, tumor-specific T cells (TCRVβ8+, red)
can be seen contacting MHC-II+ (green)
cells. CT, soft connective tissue; M, striated
muscle; S, skin; v, blood vessel. Hoechst
(blue) stains cell nuclei.T cells at the same time point (Figure 2B). Interestingly,
the recruitment of macrophages was dependent on the
presence of myeloma cells and was not caused by the
Matrigel itself since very few macrophages infiltrated
cell-free Matrigel plugs (Figure 4D).
In order to demonstrate that the observed macro-
phage activation was mediated by the tumor-specific
CD4+ T cells, we performed two in vivo experiments
with blocking monoclonal antibodies (mAb). First, we
used an anti-CD4 mAb to deplete CD4+ T cells in TCR-
transgenic SCID mice. The activation of Matrigel-infiltrat-
ing macrophages was completely blocked in such CD4+
T cell-depleted mice (Figure 5A). In a second experi-
ment, we took advantage of an anti-MHC-II I-E mAb
(Dembic et al., 2004) to block the activation of tumor-specific CD4+ T cells in draining LN (Figure 5B). Such
blocking of T cell activation inhibited the migration of T
cells into Matrigel (Figure 5C), indicating that priming in
draining LN is a prerequisite for the migration of tumor-
specific CD4+ T cells to the incipient tumor site. More-
over, blocking of T cell activation and migration with
anti-MHC-II mAb completely inhibited macrophage ac-
tivation in the Matrigel plugs, as measured by MHC-II
I-A and CD11a levels (Figures 5D and 5E).
Antigen-Specific Activation of Matrigel-Infiltrating
Macrophages by CD4+ T Cells
The antigen specificity of macrophage activation by
CD4+ T cells was tested by injecting Id-specific TCR-
transgenic SCID mice with either MOPC315 or the con-
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(A) A TCR-transgenic SCID mouse was injected with GFP-labeled MOPC315 cells in Matrigel. The cellular content of the Matrigel plug was
analyzed by flow cytometry at day +5, revealing three distinct populations: CD11b+ cells (R1), GFP−CD11b− cells (R2), and GFP+ tumors cells
(R3). MHC-II expression was almost exclusively restricted to the CD11b+ population (R1), while the myeloma cells (R3) were negative for
MHC-II.
(B) TCR-transgenic SCID or SCID mice were injected with Matrigel containing MOPC315. The expression of various markers on gated
Matrigel-infiltrating CD11b+ cells was analyzed by flow cytometry at day +6.
(C) MOPC315 cells were injected s.c. in Matrigel, and MHC-II expression on Matrigel-infiltrating CD11b+ cells was measured by flow cytometry
at day +5 in a TCR-transgenic SCID mouse (shaded area) as compared to a SCID mouse (boldface line).
(D) TCR-transgenic SCID or SCID mice were injected with either MOPC315-containing Matrigel or cell-free, PBS-containing Matrigel. At
various time points after injection, the Matrigel-infiltrating CD11b+ cells were counted and divided into MHC-II high (hatched area) or low
(blank area) expressers, as defined in (C). Each column represents the mean of three mice (pooled organs). T cell activation in draining LN
was analyzed in parallel and the data are represented in Figure 2A. Dotted lines in (A), (B), and (C) indicate an isotype-matched control mAb.
TG, transgenic.trol J558 myeloma (Figure 6A). In contrast to MOPC315, t
iinjections with J558 did not result in macrophage acti-
vation in TCR-transgenic SCID mice (Figure 6A). In the s
osame experiment, nontransgenic SCID mice were in-
jected with MOPC315 and J558, and this confirmed ohat CD4+ T cells are needed for macrophage activation
n MOPC315-containing Matrigel (Figure 6A). These re-
ults suggest that macrophage activation is the result
f CD4+ T cell recognition of tumor antigens presented
n MHC-II molecules by Matrigel-infiltrating macro-
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377Figure 5. Primed Tumor-Specific CD4+ T
Cells Migrate to the Incipient Tumor Site,
Where They Activate Macrophages
(A) TCR-transgenic SCID mice were injected
(200 g i.p.) twice a week with either deplet-
ing anti-CD4 mAb (GK1.5) or with isotype-
matched control mAb (KT4-10), starting 1
week before the injection of MOPC315 in
Matrigel. MHC-II expression on Matrigel-
infiltrating CD11b+ macrophages was ana-
lyzed at day +6. Data for one representative
mouse in each group are shown.
(B–E) TCR-transgenic SCID (n = 8) or non-
transgenic SCID mice (n = 4) were injected
with MOPC315 cells in Matrigel. Starting at
day +2, four TCR-transgenic SCID mice were
treated daily with an anti-MHC-II I-E blocking
mAb (14-4-4S, 200 g i.p. + 200 g s.c.). The
remaining mice (four TCR-transgenic SCID
and four SCID) were left untreated. At day
+7, draining LN and Matrigel plugs were ana-
lyzed by flow cytometry. (B) CD69 expres-
sion on gated tumor-specific (GB113+) CD4+
T cells in draining LN of a nontreated (top)
or anti-I-E-treated (bottom) TCR-transgenic
SCID mouse. Similar data were obtained for
each of the four mice per group. (C) Percen-
tage of tumor-specific (GB113+) T cells in
Matrigel plugs in untreated or anti-I-E-
treated TCR-transgenic SCID mice (mean ±
SD). (D and E) Expression of the activation
markers MHC-II I-A (D) and CD11a (E) on
Matrigel-infiltrating CD11b+ cells in the three
experimental groups (mean ± SD). It should
be noted that the 14-4-4S mAb used to treat
the mice is specific for MHC-II I-E and is
therefore not expected to interfere directly
with flow cytometric measurements of the
levels of MHC-II I-A with the NIMR-4 mAb. P
values were calculated with the Mann-Whit-
ney test.phages. We therefore examined whether Matrigel-
infiltrating macrophages could present tumor-derived
Id peptides. Macrophages that had infiltrated MOPC315-
containing Matrigel plugs were purified and tested for
their ability to spontaneously stimulate Id-specific
CD4+ T cells in vitro. A modest proliferation of tumor-
specific CD4+ T cells could be detected in the absence
of added peptide, indicating an in vivo loading of the
macrophages (Figure 6B). Addition of exogenous syn-
thetic Id peptide to the cultures further improved the
proliferation, demonstrating that the Matrigel-infiltrat-
ing macrophages were potent APCs (Figure 6B). Al-
though Matrigel-infiltrating macrophages upregulate
MHC-II in TCR-transgenic mice (Figure 6A), no differ-
ence was observed in antigen presentation capacity
between macrophages isolated from TCR-transgenic
SCID versus SCID mice at day +5 (Figure 6B).
The antigen specificity of macrophage activation by
CD4+ T cells can in theory take place either (i) in drain-
ing LN, during the initial T cell priming, or (ii) in the in-
cipient tumor tissue, when CD4+ T cells interact with
macrophages. We have demonstrated above that CD4+
T cell priming in LN was indeed antigen specific (Figure2A). To assess the role of antigen presentation in the
malignant tissue, we designed an experiment in which
tumor-specific CD4+ T cells would be able to meet their
cognate antigen in the LN (and be primed), but not in
the malignant tissue. For this purpose, TCR-transgenic
SCID mice were injected with MOPC315-containing
Matrigel on the right flank and J558-containing Matrigel
on the left flank (Figures 6C–6E). At day 6 after injection,
Matrigel plugs and draining LN were analyzed individu-
ally. Several observations could be made from this ex-
periment. First, Id-specific CD4+ T cells became acti-
vated in the right flank LN, draining MOPC315-
containing Matrigel, but not in the left flank LN, draining
J558-containing Matrigel (Figure 6C, upper part). This
demonstrates that the initial priming of tumor-specific
CD4+ T cells is taking place locally, in the LN draining
the malignant tissue, rather than systemically. Second,
primed Id-specific CD4+ T cells migrated to the same
extent into both MOPC315- and J558-containing Matri-
gel plugs (Figure 6D, left). This reveals that, in contrast
to the priming in LN, the migration of primed CD4+ T
cells into tumor tissues is not antigen specific. Third,
macrophages were recruited to the same extent into
Immunity
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mor-Infiltrating Macrophages by CD4+ T
Cells
(A) TCR-transgenic SCID or nontransgenic
SCID mice (four mice per group) were in-
jected with Matrigel containing either
MOPC315 or J558 cells. MHC-II expression
(mean ± SD) on gated Matrigel-infiltrating
CD11b+ cells at day +6 is represented.
(B) TCR-transgenic SCID or SCID mice were
injected with Matrigel containing MOPC315.
Matrigel-infiltrating CD11b+ cells were puri-
fied at day +5 and tested for their ability to
stimulate in vitro the proliferation of Id-spe-
cific CD4+ T cells, with or without the addi-
tion of Id peptide into the cultures.
(C–E) TCR-transgenic SCID mice (n = 5) were
injected s.c. with MOPC315-containing Mat-
rigel on the right flank and J558-containing
Matrigel on the left flank. At day +6, Matrigel
plugs and draining LN were analyzed indi-
vidually. (C) A representative mouse. Up-
per part, expression of CD69 on gated
CD4+GB113+ T cells in LN draining the left
and the right flank. Lower part, expression
of MHC-II on gated CD11b+ cells that had
infiltrated the Matrigel plugs containing
either J558 (left) or MOPC315 (right). The
dotted line indicates an isotype-matched
control mAb. (D) Frequency and CD69
expression levels of Matrigel-infiltrating
GB113+TCRCβ+ T cells (mean ± SD). (E) Fre-
quency and MHC-II expression levels of Ma-
trigel-infiltrating CD11b+ cells (mean ± SD).
P values were calculated with the (A) un-
paired t test and the (D and E) Mann-Whitney
test. MFI, mean fluorescence intensity; NS,
not statistically significant; TG, transgenic.MOPC315- and J558-containing Matrigel plugs (Fig- p
ure 6E, left). Fourth, macrophages were activated in 1
MOPC315-containing Matrigel, but not in Matrigel with g
J558, demonstrating the importance of antigen pre- T
sentation in situ for T cell-mediated macrophage acti- i
vation (Figures 6C, lower part, and 6E, right). Fifth, the c
levels of CD69 on Matrigel-infiltrating T cells were t
higher in the MOPC315-containing Matrigel plug as a
compared to the J558-containing Matrigel plug. This w
strongly suggests that T cell recognition of tumor- N
derived peptides presented on MHC-II by macro- n
phages results in reactivation of the tumor-specific r
CD4+ T cells in situ at the incipient tumor site (Figure t
6D, right). c
cIFN Is Critical for T Cell-Mediated Macrophage
uActivation and Tumor Rejection
tWe have shown in Figure 2D that Matrigel-infiltrating
tumor-specific CD4+ T cells produce IFNγ, which is a sotent macrophage activation factor (Steeg et al.,
982). To test whether the observed activation of Matri-
el-infiltrating macrophages was dependent on IFNγ,
CR-transgenic SCID mice were injected with a block-
ng anti-IFNγ mAb. Such a treatment affected neither T
ell activation in draining LN nor T cell migration into
he Matrigel plug (Figure S1). In contrast, T cell-medi-
ted activation of Matrigel-infiltrating macrophages
as completely inhibited by blocking IFNγ (Figure 7A).
otably, macrophage activation could be restored in
ontransgenic SCID mice by s.c. injection with mouse
ecombinant IFNγ (Figure 7A). Thus, IFNγ is critical for ac-
ivation of the macrophages that infiltrate the MOPC315-
ontaining Matrigel plugs.
Macrophage activation by IFNγ is referred to as the
lassical activation pathway and is characterized by
pregulation of surface FcγRII/III. A number of alterna-
ive pathways for macrophage activation, which are as-
ociated with upregulation of receptors like FcRII
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tivation and Tumor Rejection
(A) TCR-transgenic SCID and SCID mice
were injected with Matrigel containing
MOPC315 cells. At day +1 and +4, groups of
mice were treated with either blocking anti-
IFNγ mAb (XMG1.2, 100 g i.p. + 100 g
s.c.), isotype-matched control mAb (187.1,
100 g i.p. + 100 g s.c.), or mouse recombi-
nant IFNγ (2 × 103 U, s.c.), or they were left
untreated. At day +6, MHC-II expression on
Matrigel-infiltrating CD11b+ cells was ana-
lyzed by flow cytometry (mean ± SD).
(B) TCR-transgenic SCID mice were chal-
lenged s.c. with MOPC315 cells in PBS and
injected three times a week with either
blocking anti-IFNγ mAb or isotype-matched
control mAb (100 g i.p. + 100 g s.c.). Tu-
mor growth was recorded over time.
(C) SCID mice were challenged s.c. with
MOPC315 cells in PBS and injected s.c.
three times a week with recombinant mouse
IFNγ (2 × 103 U, s.c.) or were left untreated.
Palpable tumors were recorded over time.
(D) TCR-transgenic SCID and SCID mice
were injected with Matrigel containing
MOPC315. Matrigel-infiltrating CD11b+ cells
were purified at day +7 and tested at various
effector to target ratios for their ability to
suppress the proliferation (mean cpm ± SD)
of MOPC315 cells in vitro in a growth inhibi-
tion assay. In the same experiment, the di-
rect cytotoxicity of IFNγ (5000 U/ml) on
MOPC315 was tested. P values were calcu-
lated with the (A) unpaired t test and the (B
and C) logrank test.(CD23), scavenger RI (CD204), and mannose R (CD206),
have been described (Mantovani et al., 2004). Flow
cytometry analysis confirmed that Matrigel-infiltrating
macrophages in TCR-transgenic SCID mice have a
classical activation phenotype (FcγRII/IIIhi, CD23−,
CD204lo/−, CD206 lo/−), in accordance with their IFNγ-
mediated activation (Figure S2).
The observations reported above prompted us to in-
vestigate the importance of IFNγ in tumor rejection. In
a first experiment, blockage of IFNγ rendered the TCR-
transgenic SCID mice susceptible to MOPC315 tumor
development, revealing that the antitumor response
was dependent on IFNγ (Figure 7B). In a second com-
plementary experiment, s.c. injection with mouse re-
combinant IFNγ was shown to significantly delay
MOPC315 tumor growth in SCID mice (Figure 7C). Thisindicates that the antitumor function of tumor-specific
CD4+ T cells can at least partly be substituted with local
injection of IFNγ.
T Cell-Activated Macrophages Suppress
Tumor Cell Growth
Our data revealed that the primary antimyeloma im-
mune response is associated with secretion of IFNγ by
tumor-specific CD4+ T cells, resulting in activation of
macrophages in close proximity to the tumor cells. This
prompted us to test whether IFNγ and T cell-activated
macrophages could directly exert tumor suppressive
functions. Addition of IFNγ in high concentration to
MOPC315 cells in vitro had no effect on cell prolifera-
tion, demonstrating that IFNγ per se was not directly
cytotoxic to the myeloma cells (Figure 7D). Similarly,
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cSCID mice had no influence on MOPC315 in vitro
agrowth (Figure 7D). In striking contrast, Matrigel-infil-
itrating macrophages isolated from TCR-transgenic
SCID mice at day +7 were able to completely inhibit
tthe in vitro proliferation of MOPC315 cells in a dose-
cdependent manner (Figure 7D). These results demon-
astrate that Matrigel-infiltrating macrophages that have
sbeen activated in vivo by tumor-specific CD4+ T cells
pcan effectively inhibit the growth of MOPC315 cells in
Lvitro. Since the suppression of tumor cell growth was
Cobserved in a short-term (2.5 days) ex vivo assay, it is
plikely that the activated macrophages exert the same
Minhibitory function in vivo.
p
iDiscussion
w
sA series of recent reports have shed light on the various
2strategies used by the immune system to recognize
mand eliminate newly transformed cells. A number of
rlymphocyte subsets (like CD8+ T cells, γδ T cells, NK
ecells, and NKT cells) and effector mechanisms (such as
IFNγ, perforin, and TRAIL) have been shown to be criti-
tcal for immunosurveillance against various types of
emalignancies (Girardi et al., 2001; Kaplan et al., 1998;
sShankaran et al., 2001; Smyth et al., 2000a, 2000b;
tStreet et al., 2002; Takeda et al., 2002).
rTo our knowledge, our data provide the first descrip-
ttion of a successful primary antitumor immune re-
(sponse mediated by CD4+ T cells. Several obstacles
ohave previously hindered such a study: (i) the exact
itime and localization of cellular transformation leading
wto malignancy are close to impossible to determine, (ii)
pT cells specific for a given antigen are extremely infre-
Hquent (<10−6) and therefore difficult to detect, before
c
they become activated and clonally expand, and (iii)
m
when immunosurveillance is successful, transformed
b
cells are rapidly eliminated by the immune system,
e
leaving no tumor specimen for investigation. We cir- c
cumvented these problems by transplanting syngeneic T
tumor cells embedded in a collagen gel into TCR-trans- a
genic mice with high numbers of naive tumor-specific t
CD4+ T cells. p
Our data illustrate that naive tumor-specific CD4+ T
cells can efficiently be primed in the draining LN within d
3–6 days after s.c. injection of tumor cells. This initial t
activation results in changes in the displayed cell sur- b
face molecules, allowing the tumor-specific CD4+ T t
cells to leave the lymphoid organ and to migrate to the g
incipient tumor site. l
Characterization of the early immunological events at h
the incipient tumor site was made possible by embed- c
ding the injected myeloma cells in Matrigel. Matrigel c
is a soluble basement membrane that is derived from a m
murine tumor and therefore represents a genuine tumor r
cell microenvironment (Kleinman et al., 1986). Matrigel i
constituents (mainly laminin, type IV collagen, and v
heparan sulfate proteoglycan) are physiological com- c
ponents of the extracellular matrix and thus are not w
expected to hinder migration of leukocytes. Indeed, s
already 3 days after injection, myeloma-containing 2
Matrigel plugs were massively infiltrated by macro-
mphages, apparently recruited by chemoattractants se-reted by tumor cells (Bottazzi et al., 1983). Tumor-spe-
ific CD4+ T cells, previously primed in the LN, arrived
few days later and interacted with the macrophages
nside the Matrigel plug.
MOPC315, like most cancer cells, lacks MHC-II and
herefore cannot be directly recognized by tumor-spe-
ific CD4+ T cells. However, our data reveal that the
ntigen specificity of the anti-MOPC315 immune re-
ponse is ensured at two checkpoints: (i) during the
riming of naive tumor-specific CD4+ T cells in draining
N, and (ii) in the malignant tissue, when tumor-specific
D4+ T cells are reactivated by infiltrating macro-
hages that present tumor-derived peptides on their
HC-II molecules. Macrophages were identified as the
redominant APCs at the incipient tumor site. This find-
ng contrasts with previous studies in large tumors in
hich dendritic cells were reported to activate tumor-
pecific T cells (Chiodoni et al., 1999; Dembic et al.,
000, 2001). Our results suggest that the microenviron-
ent surrounding newly transformed cells being mac-
ophage enriched might be quite different from that of
stablished tumors, which is dendritic cell enriched.
Upon recognition of tumor-derived antigenic pep-
ides presented on MHC-II by macrophages, the my-
loma-specific CD4+ T cells were reactivated and
tarted to secrete IFNγ and TNFα in close proximity to
he tumor cells. T cell-derived IFNγ was shown to be
equired for MOPC315 rejection, providing support for
he important role of IFNγ in cancer immunosurveillance
Kaplan et al., 1998; Street et al., 2002). The function
f TNFα was not investigated in the present study. An
nteresting possibility is that TNFα may act in synergy
ith IFNγ for the activation of tumoricidal macro-
hages, as previously shown in vitro (Hori et al., 1987).
owever, it should be noted that the role of TNFα in
ancer is a subject of debate, since both tumor-pro-
oting and tumor-suppressing effects of TNFα have
een reported (Balkwill, 2002). Conceivably, FasLigand
xpression on activated tumor-specific CD4+ T cells
ould also contribute to tumor rejection. However,
CR-transgenic mice homozygous for the gld mutation
re still able to reject MOPC315 cells, demonstrating
hat FasLigand is dispensable for tumor protection (un-
ublished data).
Our results suggest that an important role of T cell-
erived IFNγ is to activate the antitumor effector func-
ions of macrophages. Activated macrophages have
een reported to secrete a number of compounds with
umoricidal activity, like nitric oxide and reactive oxy-
en intermediates (Mantovani et al., 2004). The molecu-
ar mechanisms whereby activated macrophages in-
ibit MOPC315 cell growth in our in vivo model are
urrently under investigation. IFNγ was shown to be
rucial for macrophage activation, but additional antitu-
or effects of IFNγ were not excluded. IFNγ did not di-
ectly kill or inhibit the proliferation of MOPC315 cells
n vitro. However, IFNγ could inhibit tumor growth in
ivo by inducing the production of antiangiogenic
hemokines by the tumor cells or by stromal cells
ithin the tumor microenvironment, as reported in other
ystems (Coughlin et al., 1998; Qin and Blankenstein,
000).
It is well established that solid tumors are infiltrated by
acrophages, but the function of these tumor-associated
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381macrophages (TAMs) is controversial. Initial studies re-
vealed that peritoneal macrophages from immunized
mice could kill tumor cells in vitro, and the reaction was
shown to be immunologically specific (Evans and Alex-
ander, 1970). Subsequent in vitro studies demonstrated
that macrophages could be rendered tumoricidal by
treatment with IFNγ (Schreiber et al., 1983). However,
extensive infiltration of tumors by macrophages is often
associated with poor prognosis (Bingle et al., 2002).
Therefore, it was proposed that the tumor microenvi-
ronment may educate TAMs so that they produce im-
portant growth factors and enzymes that stimulate an-
giogenesis and tumor growth (Bingle et al., 2002;
Mantovani et al., 2004; Pollard, 2004). More specifically,
tumor cells have been suggested to redirect TAM activ-
ity by secreting cytokines like IL-10 and TGF-β. Thus,
TAMs may have either tumor-suppressing or tumor-pro-
moting functions, depending on their activation state.
Our data obtained in a mouse model for myeloma sug-
gest that tumor-specific CD4+ T cells may have a piv-
otal role in preventing early tumorigenesis by secreting
IFNγ and inducing the classical macrophage activation
pathway that results in inhibition of tumor cell growth.
Experimental Procedures
Mice, Cell Lines, and Injection of Tumor Cells
Id-specific TCR-transgenic SCID mice or SCID littermates on a
BALB/c background (Bogen et al., 1992, 1995) were bred in a het-
erozygous (nontransgenic SCID × TCR-transgenic SCID) state by
Taconic (Ry, Denmark). MOPC315 (IgA, λ2315) and J558 (IgA, λ1) are
transplantable BALB/c plasmacytomas obtained from American
Type Culture Collection (ATCC, Manassas) and propagated as in
vitro growing cells. The MOPC-GFP cell line has been described
(Dellacasagrande et al., 2003). Tumor cells were washed once in
PBS (GIBCO-BRL, Carlsbad, CA) and suspended in PBS prior to
s.c. injection in the interscapular region or in the flank. Adult mice
were injected with 1–1.6 × 105 tumor cells suspended either in 100
l PBS or in 300 l Growth Factor Reduced Matrigel (BD Biosci-
ences, San Diego, CA). The study was approved by the National
Committee for Animal Experiments (Oslo, Norway).
Antibodies, ELISA, IFN
The following commercially available mAbs were used, conjugated
with either FITC, PE, allophycocyanin (APC), Alexa 546, or biotin:
CD4 (RM4.5 or GK1.5), CD8 (53-6.7), CD11b (M1/70), CD11c (HL3),
CD23 (B3B4), CD44 (IM7), CD45R/B220 (RA3-6B2), CD54 (3E2),
CD138 (281-2), MHC-II I-A/I-E (M5/114.15.2), TCRCβ (H57-597),
Mac-3 (M3/84) (PharMingen, San Diego, CA); CD11a (I21/7), CD62L
(MEL-14), CD69 (H1.2F3), CD80 (1G10), CD86 (GL1), MHC-II I-A
(NIMR-4), (Southern Biotechnology, Birmingham, AL); CD204 (2F8),
CD206 (MR5D3) (Serotec, Oxford, UK); von Willebrand factor (Dako,
Glostrup, Denmark); goat anti-mouse IgG (Molecular Probes, Eu-
gene, OR); donkey anti-rat IgG, donkey anti-mouse IgG, donkey
anti-rabbit IgG (Jackson ImmunoResearch, CA). The following
mAbs were affinity purified and conjugated with FITC or biotin in
our laboratory: transgenic-TCR-clonotype (GB113), MHC-II I-E (14-
4-4S; ATCC), F4/80 (HB198, ATCC), TCR Vβ8 (F23.1), FcγRII/III
(2.4G2; ATCC), IFNγ (XMG1.2), M315 (Ab2.1-4), Ig Cα (8D2), Ig κ-
chain (187.1). M315 myeloma protein in serum was quantified by
ELISA (Lauritzsen and Bogen, 1993). Mouse recombinant IFNγ was
a kind gift from Dr. G. Garotta (Hoffmann-La Roche, Basel, Swit-
zerland).
Analysis of Cells by Flow Cytometry
Matrigel plugs were treated with collagenase and DNase (both from
Sigma, St. Louis) at 37°C for 30 min to release the cells. Single-cell
suspensions from draining (axillaris + inguinal) LN were made by
squeezing LN through a stainless steel sieve (Sigma). Unspecificbinding was blocked by incubation with heat-inactivated 30% nor-
mal rat serum in PBS and 100 g/ml anti-FcγRII/III mAb (2.4G2)
prior to staining with specific mAbs. Biotinylated mAbs were de-
tected with streptavidin conjugated to peridinin chlorophyll protein
(PerCP, PharMingen). For measurement of DNA synthesis, mice
were treated with BrdU i.p. (2 × 1 mg on day +3 and +7 after tumor
cell injection), and it was added to their drinking water (0.8 mg/ml,
starting on day +3), before staining at day +9 with APC BrdU flow
kit (BD Biosciences). For intracellular cytokine detection, cells were
stimulated with the phorbol myristate acetate and ionomycin (both
from Sigma) in vitro for 6 hr in cell culture medium supplemented
with monensin prior to staining with Cytofix/Cytosperm Plus rea-
gents (PharMingen) and specific mAbs. Quadruple-stained cells
were analyzed on a FACScalibur instrument with CELLQUEST soft-
ware (BD Biosciences).
Immunohistochemistry
Upon termination of the experiment, the Matrigel plugs were re-
moved by a wide excision of the flank wall, including the skin and
all muscle layers, and transferred to PBS on ice. Each specimen
was then divided into two pieces, one being immediately snap fro-
zen (liquid N2) in OCT compound (Sakura, Torrance, CA) for storage
at −70°C until use, the other being fixed for 24 hr in methanol
(−20°C) and further processed as follows: 96% ethanol (24 hr, 4°C),
absolute ethanol (2 hr, 4°C) twice, xylene twice (20 hr, 4°C and 30
min, 22°C) prior to paraffin embedding. All of the following steps
were performed at 22°C unless otherwise noted. Frozen tissue sec-
tions (8 m) were air dried overnight and subsequently acetone-
fixed. Paraffin sections (4 m) were dried for 24 hr at 4°C, dewaxed
with xylene, and bathed consecutively in absolute ethanol, 96%
ethanol, 70% ethanol, and PBS before staining. Cryosections were
incubated with the primary and secondary reagents for 1 hr each,
whereas paraffin sections were incubated with primary antibodies
for 20 hr and secondary reagents for 3 hr, repsectively. In some
experiments Hoechst blue nuclear stain was added to the final vol-
ume of washing buffer after the last incubation. Negative controls
were tissue sections incubated with primary irrelevant isotype- and
concentration-matched mAbs. Microscopy was performed with a
Nikon E-800 fluorescence microscope (Nikon Corp., Tokyo, Japan)
equipped with a F-view digital camera controlled by the analySIS
3.2 software (Soft Imaging System GmbH, Munster, Germany).
T Cell Proliferation Assay
Matrigel-infiltrating CD11b+ cells were purified by FACSDiVa (BD
Biosciences) at day 5 after s.c. injection. Sorted CD11b+ cells
(R96% pure) were irradiated (2000 rad) and used as stimulators
(5 × 104 cells per well). Responders (2 × 104 cells per well) were
short-term cultured Th2-polarized LN cells from TCR-transgenic
mice (Munthe et al., 1999). An optimal concentration of the Id 89-
107 synthetic peptide (4 µg/ml) was added to the positive control.
Cultures were pulsed with [3H]thymidine (Montebello Diagnostics,
Oslo, Norway) after 72 hr and harvested 12 hr later on a TopCount
NXT microplate counter (Packard, Meriden, CT).
Tumor Cell Growth Inhibition Assay
Matrigel-infiltrating CD11b+ cells were purified by FACSDiVa at day
7 after s.c. injection. Sorted CD11b+ cells (R98% pure) were irradi-
ated (2000 rad) and added at various effector:target ratios to
MOPC315 cell cultures (104 tumor cells/well). Alternatively,
MOPC315 cells were cultured in the presence of 5000 U/ml mouse
recombinant IFNγ. Cultures were pulsed with [3H]thymidine after 48
hr and harvested 12 hr later on a TopCount NXT microplate counter.
Supplemental Data
Supplemental Data including an Experimental Procedures section
detailing immunohistochemistry and two figures are available with
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